AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 32 min read$ALEC

Rosenthal Arnon sold $172K of ALEC

Rosenthal Arnon (Chief Executive Officer) sold 87,216 shares of Alector, Inc. (ALEC) at $1.97 ($0.17M total) on 2026-06-02.

Original reporting
SEC EDGAR · Rosenthal Arnon
Published Jun 3, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALEC
Neutral
medium confidence
Mentioned
$ALEC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALECNeutralLow
01

Why it matters

This provides a concrete insider selling datapoint (shares, price, and remaining holdings) but no new operational or clinical information.

02

Market read

Traders may monitor ALEC for sentiment drift or continued insider selling, but the filing alone is unlikely to drive a major repricing.

03

What to watch

No 10b5-1 plan is stated, but Form 4s alone don’t reveal intent; traders may need follow-on filings, volume/price reaction, and any concurrent corporate catalysts.

Relevance 6/10Novelty 6/10Timing: Filed after-hours/late day (2026-06-03), reflecting sale executed 2026-06-02.

Background

The article is an SEC Form 4 insider transaction disclosure for Alector, Inc. (ALEC).

Company-level read

Ticker impact

$ALECNeutralMedium confidence
Context

Alector CEO Rosenthal Arnon sold 87,216 shares in an open-market transaction, disclosing direct insider selling at $1.9743/share.

Expected impact

Likely limited, with any effect more sentiment-driven than trend-changing unless follow-on selling continues.

Evidence & confidence

The filing provides a discrete sale price/size and post-transaction holdings, but no new company fundamentals (trial, guidance, deal) are disclosed.

Market effects

Sector

Minimal sector read-through; this is company-specific insider activity without broader industry news.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be routine liquidity/portfolio management rather than a bearish signal, especially given the large remaining holdings.

Key entities

  • issuer
    Alector, Inc.

    Subject of the SEC Form 4 insider sale by the CEO.

  • insider
    Rosenthal Arnon

    CEO/Officer/Director who sold 87,216 shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALEC insider trading history →

Related articles

OCT 7
MedAI 8/10

Genentech pays Alector $100m for Parkinson drug

Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.

bioxconomy.com2 min
OCT 6
HighAI 9/10

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Roche will pay up to $1.27 billion to license Alector's experimental Parkinson's therapy, AL050. The deal includes a $100 million upfront payment and potential milestone payments. Alector's shares surged 72% in premarket trading. Roche's Genentech unit will handle development and commercialization, with Alector eligible for royalties.

ksl.com2 min
OCT 5
$ALECHigh

Alector (ALEC) Shares Jump 22% on Genentech Licensing Deal for A

Alector Inc (ALEC) shares rose 22% after announcing a licensing deal with Genentech for its AL050 program. The deal includes a $100M upfront payment and potential milestone payments up to $1.17B. Alector's P/S ratio is 17.46, higher than historical and industry averages, reflecting growth expectations. The company's GF Score is 31/100, indicating weak fundamentals but some momentum.

gurufocus.com2 min